Confirm the molecular diagnosis before disease-specific treatment
Friedreich ataxia should not be diagnosed from gait ataxia alone. The typical disease is linked to FXN dysfunction, most often from GAA-repeat expansions. A specialist should review the exact laboratory method, repeat findings or sequence variants and whether the genotype fits the phenotype before omaveloxolone or family counseling is discussed.
The neurological phenotype extends beyond cerebellar coordination
Friedreich ataxia can involve gait and limb ataxia, sensory loss, weakness, dysarthria, pyramidal signs and progressive mobility impairment. Bonn, Heidelberg and Charité place the disease within specialist hereditary-ataxia pathways because clinical overlap with other recessive, dominant, mitochondrial and acquired ataxias can otherwise delay the correct diagnosis.
Omaveloxolone is an authorised option from age 16, not a cure
EMA states that Skyclarys (omaveloxolone) is authorised in the EU for Friedreich ataxia in adults and adolescents aged 16 years and older and must be initiated and supervised by an experienced physician. Treatment can reduce physical impairment compared with placebo in studied patients, but it does not reverse the genetic disorder. Eligibility, contraindications, interactions and monitoring should be reviewed individually.
Medication monitoring includes liver tests and interaction review
EMA lists increases in liver enzymes among common adverse effects and notes clinically relevant interactions with CYP3A inhibitors. Before and during treatment, the specialist should review medications, liver-related laboratory monitoring, weight and adverse effects rather than treating omaveloxolone as a simple travel prescription.
Cardiomyopathy and rhythm risk require dedicated surveillance
Cardiac involvement is a core multisystem feature of Friedreich ataxia. A German second opinion may coordinate ECG, echocardiography, cardiac MRI or rhythm monitoring according to previous findings and symptoms. Neurological improvement alone does not remove the need for cardiac follow-up.
Diabetes and metabolic complications should be assessed alongside neurology
EMA and specialist-center information identify diabetes as an important non-neurological complication. Glucose/HbA1c and broader metabolic review should therefore be included when clinically appropriate, especially before long-term treatment planning.
Rehabilitation remains essential even with disease-modifying medication
Heidelberg emphasizes rehabilitation as a key element of hereditary-ataxia treatment. Physiotherapy, balance and gait training, occupational therapy, speech/swallowing therapy, mobility aids and fall prevention remain important because a disease-modifying drug does not replace functional care.
Orthopedic and mobility problems need phenotype-specific planning
Scoliosis, pes cavus, contractures and progressive mobility limitations can influence function and care needs. Orthopedic review should be driven by symptoms and functional goals. Surgery, bracing, orthotics and wheelchair planning are separate decisions rather than routine components of one Friedreich package.
Genetic counseling should address autosomal-recessive inheritance
A confirmed FXN diagnosis has implications for siblings, partners and reproductive planning. Genetic counseling can explain carrier testing and family risk without automatically testing asymptomatic relatives before informed discussion.
Gene therapy and other pipeline approaches are still research
EMA orphan designations and clinical research show an active Friedreich pipeline, including gene-based approaches, but orphan designation is not marketing authorisation. Experimental protocols must remain clearly separated from Skyclarys and other established supportive care.
What to send for a German Friedreich ataxia second opinion
The receiving team should be able to confirm the diagnosis and see both neurological and multisystem status before proposing travel.
- Complete FXN genetic report including GAA-repeat findings and sequence variants
- Neurology/ataxia clinic reports and progression history
- Functional scores or physiotherapy assessments if available
- ECG, echocardiography, cardiac MRI and rhythm-monitoring records
- Glucose/HbA1c and relevant laboratory results
- Spine/orthopedic reports for scoliosis or foot deformity
- Speech/swallowing and mobility-aid records
- Current medication including omaveloxolone if already prescribed
- Liver-test results and medication-interaction list for Skyclarys review
- A specific question: confirm diagnosis, evaluate Skyclarys, review progression, cardiac risk, rehabilitation, genetics or trial eligibility
Official sources
Sources last checked 2026-09-02. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.